SolaranRx is focused on developing a new class of therapies and companion imaging agents to treat metastatic melanoma. It has developed a Precision Theranostic Platform™ that targets metastatic melanoma tumors with a radiolabeled peptide. It claims that the technology has a therapeutic potential with minimum side effects. SolaranRx is focused on developing its lead product SRX-1177, a novel peptide linked to a radioisotope that preferentially attaches to melanocortin-1 (MC1) receptors. The candidate has been granted Orphan Drug designation by the FDA based on compelling pre-clinical evidence.
Company Details
- Employees
- 12
- Address
- 5901 Indian School Rd Ne, Albuquerque,new Mexico 87110,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.solaranrxinc.com
- Keywords
- for Renewable Energy.
- HQ
- Albuquerque, New Mexico
Solaranrx Questions
Solaranrx's website is https://www.solaranrxinc.com
Solaranrx's LinkedIn profile is https://www.linkedin.com/company/solaranrx
Solaranrx has
12 employees.
View email and phone details for 12
employees at Solaranrx.
Solaranrx's industry is
Biotechnology Research
Solaranrx's top competitors are
Flourish Research,
Inner Reach Therapeutics, Llc,
Direct Supply, Inc.,
Pyramid Consulting, Inc,
Stellar Options,
Solaran,
At The Well Project,
The Bioscience Center,
New England Cell Therapeutics, Inc.,
Indulge Travels.
Solaranrx's categories are Biotechnology Research
